Through the rise of biosimilars, the evolution of patent eligibility, and the advent of hedge-fund challenges to pharma patents, Marshall Gerstein keeps a watchful eye on biotechnology and life sciences PTAB developments.
Marshall Gerstein Elects Two New Partners
Marshall, Gerstein & Borun LLP today announced the election of Jacqueline (Jacque) J. DeFoe, Ph.D. and Conor S. Hunt to partnership, effective January 1, 2021.
“We are proud to recognize Jacque and Conor for their hard work and advocacy on behalf... More
Please note that email communications sent through this website do not create an attorney-client relationship between you and our firm, and will not prevent us from representing another person or company involved in the same matter that is the subject of your message. Unless you are already a client of Marshall, Gerstein & Borun LLP, do not send any information that you consider privileged or confidential. Click “Accept” below to confirm that you have read and understand this message.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.